CN119053329A - 利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物 - Google Patents

利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物 Download PDF

Info

Publication number
CN119053329A
CN119053329A CN202380031517.4A CN202380031517A CN119053329A CN 119053329 A CN119053329 A CN 119053329A CN 202380031517 A CN202380031517 A CN 202380031517A CN 119053329 A CN119053329 A CN 119053329A
Authority
CN
China
Prior art keywords
cancer
gene
myc
mutation
myc gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380031517.4A
Other languages
English (en)
Chinese (zh)
Inventor
户崎浩和
森下大辅
水谷明生
佐藤义彦
冰上光辉
间野博行
高阪真路
滨田哲畅
柳下薰宽
岩井谦一
矢口正宏
熊泽和帆
野村俊之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Co Kodia Pharmaceutical Co ltd
National Cancer Center Korea
Original Assignee
Japanese Co Kodia Pharmaceutical Co ltd
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Co Kodia Pharmaceutical Co ltd, National Cancer Center Korea filed Critical Japanese Co Kodia Pharmaceutical Co ltd
Publication of CN119053329A publication Critical patent/CN119053329A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380031517.4A 2022-03-31 2023-03-30 利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物 Pending CN119053329A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-060240 2022-03-31
JP2022060240 2022-03-31
PCT/JP2023/013361 WO2023190967A1 (ja) 2022-03-31 2023-03-30 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Publications (1)

Publication Number Publication Date
CN119053329A true CN119053329A (zh) 2024-11-29

Family

ID=88202235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380031517.4A Pending CN119053329A (zh) 2022-03-31 2023-03-30 利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物

Country Status (7)

Country Link
US (1) US20260108526A1 (https=)
EP (1) EP4501328A4 (https=)
JP (1) JPWO2023190967A1 (https=)
KR (1) KR20240169002A (https=)
CN (1) CN119053329A (https=)
CA (1) CA3246851A1 (https=)
WO (1) WO2023190967A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025150571A1 (ja) * 2024-01-12 2025-07-17 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 Ｃｌｋ阻害剤を有効成分として含むがん治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.
US11946934B2 (en) * 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
US10577382B2 (en) 2016-04-28 2020-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP7224645B2 (ja) 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法

Also Published As

Publication number Publication date
EP4501328A1 (en) 2025-02-05
WO2023190967A1 (ja) 2023-10-05
JPWO2023190967A1 (https=) 2023-10-05
CA3246851A1 (en) 2025-02-03
KR20240169002A (ko) 2024-12-02
US20260108526A1 (en) 2026-04-23
EP4501328A4 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
US20240392378A1 (en) Methods of treating cancer
Yen et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Chae et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Brambilla et al. Pathogenesis of lung cancer signaling pathways: roadmap for therapies
Puzio-Kuter et al. Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator
CN103402517A (zh) 使用braf抑制剂的治疗方法
EP2912194B1 (en) Androgen receptor variants and methods for making and using
ES2622401T3 (es) Método de predicción de la eficacia de un inhibidor de la angiogénesis
WO2012177925A1 (en) Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
JP2018050625A (ja) 癌治療に対する感受性を予測するためのバイオマーカー
CN119053329A (zh) 利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物
EP3908282B1 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
CN103764847A (zh) 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法
WO2006073202A9 (ja) GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法
Guan et al. Molecular determinants of clinical outcomes for anaplastic lymphoma kinase–positive non-small cell lung cancer in Chinese patients: a retrospective study
Ritu et al. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
WO2015066432A1 (en) Method of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia
JP7747459B2 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
HK40112492A (zh) 利用咪唑并[4，5-b]吡啶衍生物治疗实体瘤的生物标志物
Mondal et al. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways. Cells 2024, 13, 1221. h ps
JP5119546B2 (ja) 胃を原発巣とする消化管間質腫瘍の悪性化の診断法
Wanigasooriya Improving response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Deenichina Investigating the role of FOSL1/FRA1 in BRAF-V600E patient-derived colorectal cancer organoids
Mazza New molecular drivers in NSCLC: The role of MET
Vakiani GI Including GIST

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112492

Country of ref document: HK